Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative

Frontiers in Medicine

article

Maria de Fátima Brito¹  Carla Torre²  Beatriz Silva-Lima¹ 

[1]Faculty of Pharmacy, University of Lisbon

[2]Laboratory of Systems Integration Pharmacology, Clinical & Regulatory Science–Research Institute for Medicines (iMED.ULisboa)

关键词: innovative medicines initiative;    diabetes;    complications of diabetes;    personalized medicine;    type 2 diabetes;    type 1 diabetes;   

DOI  :  10.3389/fmed.2021.688438

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Diabetes Mellitus is one of the World Health Organization's priority diseases under research by the first and second programmes of Innovative Medicines Initiative, with the acronyms IMI1 and IMI2, respectively. Up to October of 2019, 13 projects were funded by IMI for Diabetes & Metabolic disorders, namely SUMMIT, IMIDIA, DIRECT, StemBANCC, EMIF, EBiSC, INNODIA, RHAPSODY, BEAT-DKD, LITMUS, Hypo-RESOLVE, IM2PACT, and CARDIATEAM. In general, a total of €447 249 438 was spent by IMI in the area of Diabetes. In order to prompt a better integration of achievements between the different projects, we perform a literature review and used three data sources, namely the official project's websites, the contact with the project's coordinators and co-coordinator, and the CORDIS database. From the 662 citations identified, 185 were included. The data collected were integrated into the objectives proposed for the four IMI2 program research axes: (1) target and biomarker identification, (2) innovative clinical trials paradigms, (3) innovative medicines, and (4) patient-tailored adherence programmes. The IMI funded projects identified new biomarkers, medical and research tools, determinants of inter-individual variability, relevant pathways, clinical trial designs, clinical endpoints, therapeutic targets and concepts, pharmacologic agents, large-scale production strategies, and patient-centered predictive models for diabetes and its complications. Taking into account the scientific data produced, we provided a joint vision with strategies for integrating personalized medicine into healthcare practice. The major limitations of this article were the large gap of data in the libraries on the official project websites and even the Cordis database was not complete and up to date.

【 授权许可】

CC BY